Compare Davita Inc (DVA) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Schwab US Dividend Equity ETF — how do they compare? Davita Inc trades at $178.35 (market cap $11.72B), while Schwab US Dividend Equity ETF trades at $34.28. The key difference: Schwab US Dividend Equity ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | SCHD | |
|---|---|---|
Market Cap | $11.72B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $240.96 | $34.19 |
52-Week Low | $103.87 | $26.44 |
Enterprise Value | $24.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
SCHD, the Schwab U.S. Dividend Equity ETF, trades at $33.90, up 0.59% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on high-quality U.S. dividend-paying stocks, offering income stability. Recent news highlights its popularity among retirees for generating passive income, with institutional buying activity noted in Q2 2026 filings.
The outlook for SCHD remains positive for income-focused investors, leveraging dividend growth and low costs. Risks include interest rate sensitivity and market volatility affecting dividend stocks. Analyst sentiment is generally favorable, emphasizing its role in diversified retirement portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
